Abstract
Purpose of the Study:Radioiodine (131I) therapy is approved and well-accepted modality for the treatment of hyperthyroidism. The dosage of 131I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found that high 131I uptake values required more dose to achieve desirable results contrary to the belief.Materials and Methods:Clinically and scintigraphically proven Graves' disease patients with high 131I uptake (>50%) were accrued for this study and block randomized into low-dose (Group I) and high-dose (Group II) groups. Low activity (5 mCi) was administered in Group I and higher activity (10 mCi) in Group II. The patients were followed up after 3 months with thyroid function tests to determine the outcome.Results:A total of 344 patients were analyzed at the end of 3 months, with 174 in low-dose group and 170 in high-dose group. Euthyroidism/hypothyroidism was achieved in significantly higher number of patients as compared to the low-dose group.Conclusion:The higher dose of 131I is required to achieve euthyroidism/hypothyroidism in patients with high 131I uptake.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
